Home Pharmacogenetics: From Bench to Bedside
Article
Licensed
Unlicensed Requires Authentication

Pharmacogenetics: From Bench to Bedside

  • H. Erlich , J. Bonnet , F. W. Frueh , P. Bertrand , G. Schmitz , G. Salvatore , S. Little , C. Lambert , E. Baranova and G. Siest
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 4

Published Online: 2005-06-01
Published in Print: 2003-04-25

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
  2. Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
  3. Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
  4. The Proteome: Anno Domini 2002
  5. Cardiac Sodium Channel Diseases
  6. Haemophilia B: From Molecular Diagnosis to Gene Therapy
  7. The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
  8. Molecular Diagnostics by Microelectronic Microchips
  9. Molecular Beacons as Diagnostic Tools: Technology and Applications
  10. Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
  11. Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
  12. Impact of Purified Water Quality on Molecular Biology Experiments
  13. Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
  14. Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
  15. The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
  16. The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
  17. The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
  18. Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
  19. Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
  20. PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
  21. Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
  22. Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
  23. Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
  24. Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
  25. Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
  26. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
  27. Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
  28. Pharmacogenomics of Drugs Affecting the Cardiovascular System
  29. Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
  30. CYP3A4*1B and NAT2*14 Alleles in a Native African Population
  31. Pharmacogenetics: From Bench to Bedside
  32. Meetings and Awards
https://doi.org/10.1515/CCLM.2003.092

Articles in the same Issue

  1. First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
  2. Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
  3. Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
  4. The Proteome: Anno Domini 2002
  5. Cardiac Sodium Channel Diseases
  6. Haemophilia B: From Molecular Diagnosis to Gene Therapy
  7. The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
  8. Molecular Diagnostics by Microelectronic Microchips
  9. Molecular Beacons as Diagnostic Tools: Technology and Applications
  10. Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
  11. Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
  12. Impact of Purified Water Quality on Molecular Biology Experiments
  13. Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
  14. Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
  15. The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
  16. The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
  17. The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
  18. Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
  19. Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
  20. PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
  21. Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
  22. Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
  23. Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
  24. Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
  25. Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
  26. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
  27. Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
  28. Pharmacogenomics of Drugs Affecting the Cardiovascular System
  29. Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
  30. CYP3A4*1B and NAT2*14 Alleles in a Native African Population
  31. Pharmacogenetics: From Bench to Bedside
  32. Meetings and Awards
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.092/html
Scroll to top button